5-Ph-IAA
|
P650834-5mg
|
≥99% |
168649-23-8 |
5mg
|
¥ 2000.9
|
期货,请咨询 |
阿拉丁 |
5-Ph-IAA
|
P650834-25mg
|
≥99% |
168649-23-8 |
25mg
|
¥ 6400.9
|
期货,请咨询 |
阿拉丁 |
5-Ph-IAA
|
P650834-10mg
|
≥99% |
168649-23-8 |
10mg
|
¥ 3200.9
|
期货,请咨询 |
阿拉丁 |
P2Y2R/GPR17 antagonist 1
|
P650832-5mg
|
≥98% |
2395016-49-4 |
5mg
|
¥ 765.9
|
期货,请咨询 |
阿拉丁 |
P2Y2R/GPR17 antagonist 1
|
P650832-50mg
|
≥98% |
2395016-49-4 |
50mg
|
¥ 4050.9
|
期货,请咨询 |
阿拉丁 |
P2Y2R/GPR17 antagonist 1
|
P650832-25mg
|
≥98% |
2395016-49-4 |
25mg
|
¥ 2520.9
|
期货,请咨询 |
阿拉丁 |
P2Y2R/GPR17 antagonist 1
|
P650832-10mg
|
≥98% |
2395016-49-4 |
10mg
|
¥ 1215.9
|
期货,请咨询 |
阿拉丁 |
P2Y2R/GPR17 antagonist 1
|
P650832-100mg
|
≥98% |
2395016-49-4 |
100mg
|
¥ 6480.9
|
期货,请咨询 |
阿拉丁 |
Paeoniflorgenin
|
P650826-1mg
|
≥90% |
697300-41-7 |
1mg
|
¥ 5500.9
|
期货,请咨询 |
阿拉丁 |
PSI-7976
|
P650821-5mg
|
≥98% |
1190308-01-0 |
5mg
|
¥ 9800.9
|
期货,请咨询 |
阿拉丁 |
PSI-7976
|
P650821-1mg
|
≥98% |
1190308-01-0 |
1mg
|
¥ 4200.9
|
期货,请咨询 |
阿拉丁 |
Propofol-d17β-D-glucuronide
|
P650819-5mg
|
≥98% |
1683581-05-6 |
5mg
|
¥ 25500.9
|
期货,请咨询 |
阿拉丁 |
Propofol-d17β-D-glucuronide
|
P650819-1mg
|
≥98% |
1683581-05-6 |
1mg
|
¥ 9800.9
|
期货,请咨询 |
阿拉丁 |
(2S)-6-Prenylnaringenin
|
P650810-5mg
|
≥99% |
68236-13-5 |
5mg
|
¥ 3800.9
|
期货,请咨询 |
阿拉丁 |
(2S)-6-Prenylnaringenin
|
P650810-1mg
|
≥99% |
68236-13-5 |
1mg
|
¥ 1447.9
|
期货,请咨询 |
阿拉丁 |
(2S)-6-Prenylnaringenin
|
P650810-10mg
|
≥99% |
68236-13-5 |
10mg
|
¥ 6000.9
|
期货,请咨询 |
阿拉丁 |
PMEDAP
|
P650809-5mg
|
≥98% |
113852-41-8 |
5mg
|
¥ 1500.9
|
期货,请咨询 |
阿拉丁 |
PMEDAP
|
P650809-50mg
|
≥98% |
113852-41-8 |
50mg
|
¥ 9500.9
|
期货,请咨询 |
阿拉丁 |
PMEDAP
|
P650809-25mg
|
≥98% |
113852-41-8 |
25mg
|
¥ 5500.9
|
期货,请咨询 |
阿拉丁 |
PMEDAP
|
P650809-1mg
|
≥98% |
113852-41-8 |
1mg
|
¥ 571.9
|
期货,请咨询 |
阿拉丁 |
PMEDAP
|
P650809-10mg
|
≥98% |
113852-41-8 |
10mg
|
¥ 2500.9
|
期货,请咨询 |
阿拉丁 |
PCO371
|
P650805-5mg
|
≥98% |
1613373-33-3 |
5mg
|
¥ 3000.9
|
期货,请咨询 |
阿拉丁 |
PCO371
|
P650805-50mg
|
≥98% |
1613373-33-3 |
50mg
|
¥ 14800.9
|
期货,请咨询 |
阿拉丁 |
PCO371
|
P650805-25mg
|
≥98% |
1613373-33-3 |
25mg
|
¥ 9600.9
|
期货,请咨询 |
阿拉丁 |